Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.
about
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsThe history of neuromyelitis opticaAquaporin 4 and neuromyelitis opticaNeuroimmunological Implications of AQP4 in AstrocytesAquaporin 4: a player in cerebral edema and neuroinflammationMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeCurrent concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Experimental models of neuromyelitis optica.Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.Myasthenia gravis: an update for the clinician.Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis opticaNeuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).GRIN1 polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis.Aquaporin and brain diseasesNeuromyelitis optica: potential roles for intravenous immunoglobulin.Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica.The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis.Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.Neuromyelitis optica and myasthenia gravis in a young Nigerian girlNeuromyelitis Optica Spectrum Disorder in a Chinese Woman with Ocular Myasthenia Gravis: First Reported Case in the Chinese Population.Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients.Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD).Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica.NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.Neuromyelitis opticaLow vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disordersDiagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
Q21093230-18347583-8E75-4051-AA35-D24ABAA27922Q21245248-E856031A-89C3-46C9-83B1-D88F7B0CC777Q24613666-254FAF75-F73B-4CFC-81EE-DA218E69DCBFQ26741610-D004C387-CE25-49BC-B3E3-07B3398D3018Q27022405-0AD68B72-D9E9-4991-A2A0-ACC222BCD61BQ30371412-FCAA98AB-893C-4CC0-A03E-9C27AD7A8398Q30577078-D2C43D23-6634-4AFF-ACEE-8A144A0CF454Q30676331-26DF28FD-2E50-4E2A-931A-134D32423954Q30785267-E88BD064-6F65-4B96-BC49-3433B10CD56DQ30832651-AEA5707E-37F8-461C-A97A-2707E87B6FC8Q33591024-6A8E4185-DAEF-4C0B-BC54-8A68E93857FFQ33734731-B069C6F5-2DE3-4FCD-9605-FDC480796F04Q33785380-D9DFD711-5F7A-4BAC-83FB-F1800E4FC2C4Q34026880-99B66B72-5E7F-4360-8DE4-37F3BBBD936FQ34377145-B9C1BEDC-0B2A-4E84-BBEE-94791F3489F4Q34919661-4E7E475B-897E-4479-88FA-6BE6095967C7Q35041447-47B6805A-754E-40BD-BFA2-0193895396F8Q35052199-2A951472-5E8F-4069-B218-2C4E89682396Q36092683-DBB3FEE7-C7CD-4ACE-8C2E-DF9B43731356Q37649818-11EDA8AB-8F12-4AD2-AE3B-61DEE5148A5CQ38043401-A9F326CE-F600-4C39-9DCA-10E2DF53FD37Q38151920-4F4EA746-0DCE-4FB8-A694-3676BB9F190CQ38152822-D1E5C156-CEC9-49C5-999A-C30405C0C2F4Q38186792-96D1530C-F02E-4620-B151-A671DE6BDFA7Q38650455-9034BC19-A172-4DAE-9BBC-228D8FCF0307Q39500904-29960624-37F7-4114-A9F6-A8E94DD3AD4DQ41890538-338BF9EE-D3F0-4C5D-B366-030F40D4B491Q42075306-13B5D4C8-D8EC-42DC-9F07-46499C711480Q44938114-A5A051D9-B6AB-46B1-9D7D-89CCA684E3DAQ47104784-4F2B6FA9-DD69-4BD0-8414-11ED6EA61843Q48172406-6D1325EF-A115-4179-8A61-30C790F65D7FQ50067506-50132830-C7C2-4B24-9A2F-3CAF1328AF39Q52668258-BBF64BD4-CC6A-42CD-A00E-5EB263D693C6Q53018455-7493A1A9-9B63-4625-A0D5-888C12BB1CEDQ55384506-20DFF8AD-A1C6-43B1-8630-B8756D8A34D3Q56986418-9D95A75F-6B74-4EFF-AAB0-3E5A6026FF96Q56986463-25AEA42C-3A77-4035-B358-1CC8F8260EFDQ58573155-CD951DB3-CBFD-4B63-ADA3-3784AAEDB343
P2860
Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neuromyelitis optica spectrum ...... nd a review of the literature.
@en
Neuromyelitis optica spectrum ...... nd a review of the literature.
@nl
type
label
Neuromyelitis optica spectrum ...... nd a review of the literature.
@en
Neuromyelitis optica spectrum ...... nd a review of the literature.
@nl
prefLabel
Neuromyelitis optica spectrum ...... nd a review of the literature.
@en
Neuromyelitis optica spectrum ...... nd a review of the literature.
@nl
P2093
P2860
P921
P356
P1476
Neuromyelitis optica spectrum ...... and a review of the literature
@en
P2093
B Wildemann
D Franciotta
G Akman-Demir
K P Wandinger
K Ruprecht
M Liebetrau
M Salvetti
P2860
P304
P356
10.1177/1352458511431728
P577
2011-12-19T00:00:00Z